The risk may be fewer with bromocriptine. agonists useful for hyperprolactinemia have not demonstrated a heightened danger of valvular heart disease, but the chance must be talked about with patients, and echocardiographic surveillance should be thought of, particularly when doses > 3 mg every week are applied. The chance could be a lot less with b